Skip to Content

19,522 Results Found

  • Article
  • Open Access
6 Citations
2,959 Views
12 Pages

GATA3 as a Blood-Based RNA Biomarker for Idiopathic Parkinson’s Disease

  • Shubhra Acharya,
  • Andrew I. Lumley,
  • Lu Zhang,
  • Mélanie Vausort and ,
  • Yvan Devaux and
  • on behalf of the NCER-PD Consortium
  • + 1 author+ 0 author

Finding novel biomarkers for Parkinson’s disease (PD) is crucial for early disease diagnosis, severity assessment and identifying novel disease-modifying drug targets. Our study aimed at investigating the GATA3 mRNA levels in whole blood sample...

(This article belongs to the Special Issue Peripheral Biomarkers in Neurodegenerative Diseases 3.0)
  • Article
  • Open Access
6 Citations
3,559 Views
20 Pages

PD-1, PD-L1, and PD-L2 Expression as Predictive Markers in Rare Feline Mammary Tumors

  • Maria Franco,
  • Fernanda Seixas,
  • Maria dos Anjos Pires,
  • Anabela Alves and ,
  • Andreia Santos,
  • Carla Marrinhas,
  • Hugo Vilhena,
  • Joana Santos,
  • Pedro Faísca and
  • Fernando Ferreira
  • + 8 authors+ 3 authors

3 August 2025

Feline mammary carcinoma (FMC) exhibits aggressive behavior, with limited treatment options. Given the relevance of the PD-1/PD-L1/PD-L2 axis in human breast cancer immunotherapy, this study assessed PD-1 and its ligands in rare FMC histotypes (n = 4...

  • Article
  • Open Access
4 Citations
1,729 Views
21 Pages

Assessment of the PD-1/PD-L1/PD-L2 Immune Checkpoints Pathway in Endometrial Cancer and Its Clinical Significance

  • Karolina Włodarczyk-Ciekańska,
  • Agnieszka Kwiatkowska-Makuch,
  • Anna Pawłowska-Łachut,
  • Wiktoria Skiba and ,
  • Dorota Suszczyk,
  • Jan Kotarski,
  • Paulina Pieniądz-Feculak,
  • Anna Pańczyszyn,
  • Anna Ignatowicz and
  • Iwona Wertel
  • + 6 authors+ 1 author

29 October 2025

Background: Endometrial cancer is one of the most common female genital cancers and poses a significant clinical problem due to its increasing incidence and variable prognosis depending on the stage of the disease. The development of EC is largely de...

(This article belongs to the Special Issue Molecular Biology, Diagnosis and Management of Endometrial Cancer)
  • Review
  • Open Access
173 Citations
12,732 Views
16 Pages

PD-L1/PD-1 Axis in Glioblastoma Multiforme

  • Jakub Litak,
  • Marek Mazurek,
  • Cezary Grochowski,
  • Piotr Kamieniak and
  • Jacek Roliński

28 October 2019

Glioblastoma (GBM) is the most popular primary central nervous system cancer and has an extremely expansive course. Aggressive tumor growth correlates with short median overall survival (OS) oscillating between 14 and 17 months. The survival rate of...

(This article belongs to the Special Issue Neuroimmunology)
  • Article
  • Open Access
10 Citations
5,766 Views
16 Pages

Peptide Blockers of PD-1-PD-L1 Interaction Reinvigorate PD-1-Suppressed T Cells and Curb Tumor Growth in Mice

  • Shanshan (Jenny) Zhong,
  • Xiaoling Liu,
  • Tomonori Kaneko,
  • Yan Feng and ,
  • Owen Hovey,
  • Kyle Yang,
  • Sally Ezra,
  • Soon-Duck Ha,
  • Sung Kim and
  • Shawn Shun-Cheng Li
  • + 7 authors+ 2 authors

15 July 2024

The programmed cell death protein 1 (PD-1) plays a critical role in cancer immune evasion. Blocking the PD-1-PD-L1 interaction by monoclonal antibodies has shown remarkable clinical efficacy in treating certain types of cancer. However, antibodies ar...

(This article belongs to the Section Cellular Immunology)
  • Review
  • Open Access
22 Citations
5,884 Views
27 Pages

18 October 2021

Approximately 20% of breast cancer (BC) patients suffer from distant metastasis. The incidence and prevalence rates of metastatic BC have increased annually. Immune checkpoint inhibitors are an emerging area of treatment, especially for metastatic pa...

(This article belongs to the Special Issue Metastatic Breast Cancers)
  • Article
  • Open Access
8 Citations
3,197 Views
42 Pages

Tumor-TME Bipartite Landscape of PD-1/PD-L1 in Endometrial Cancers

  • Raed Sulaiman,
  • Pradip De,
  • Jennifer C. Aske,
  • Xiaoqian Lin and ,
  • Adam Dale,
  • Nischal Koirala,
  • Kris Gaster,
  • Luis Rojas Espaillat,
  • David Starks and
  • Nandini Dey
  • + 5 authors+ 0 author

The bipartite landscape of tumor cells and stromal cells determines a tumor’s response to treatment during disease management. In endometrial cancers (ECs), the mechanistic contribution of PD-L1/L2 and PD-1 signaling of the host’s tumor m...

(This article belongs to the Section Molecular Pharmacology)
  • Article
  • Open Access
5 Citations
2,662 Views
13 Pages

Robust Preanalytical Performance of Soluble PD-1, PD-L1 and PD-L2 Assessed by Sensitive ELISAs in Blood

  • Kimberly Krueger,
  • Zsuzsanna Mayer,
  • Marc Kottmaier,
  • Miriam Gerckens and ,
  • Stefan Boeck,
  • Peter Luppa and
  • Stefan Holdenrieder
  • + 2 authors+ 0 author

The interaction between programmed death-1 receptor PD-1 and its ligands PD-L1 and PD-L2 is involved in self-tolerance, immune escape of cancer, cardiovascular diseases, and COVID-19. As blood-based protein markers they bear great potential to improv...

(This article belongs to the Special Issue Oncoimmunity and Immunotherapy in Solid Tumors)
  • Article
  • Open Access
10 Citations
2,976 Views
13 Pages

High Quality Performance of Novel Immunoassays for the Sensitive Quantification of Soluble PD-1, PD-L1 and PD-L2 in Blood

  • Kimberly Krueger,
  • Zsuzsanna Mayer,
  • Miriam Gerckens,
  • Stefan Boeck and ,
  • Peter Luppa and
  • Stefan Holdenrieder
  • + 1 author+ 0 author

26 September 2022

Programmed death-1 receptor PD-1(CD279) and its corresponding ligands PD-L1(CD274, B7-H1) and PD-L2(CD273, B7-DC) play important roles in physiological immune tolerance and for immune escape in cancer disease. Hence, the establishment and analytical...

(This article belongs to the Special Issue Oncoimmunity and Immunotherapy in Solid Tumors)
  • Article
  • Open Access
4 Citations
3,443 Views
10 Pages

Regulation of Immunity in Clear Cell Renal Carcinoma: Role of PD-1, PD-L1, and PD-L2

  • Liudmila Spirina,
  • Zahar Yurmazov,
  • Evgeny Usynin,
  • Irina Kondakova and ,
  • Ekaterine Ladutko and
  • Evgeny Choynzonov
  • + 1 author+ 0 author

6 September 2021

Regulation of immunity is a unique oncogenic mechanism that differs in different cancers. VHL deficient clear cell renal cell carcinomas (ccRCC) trigger the immune response resulting in cancer progression. This study aimed to investigate PD-1, PD-L1,...

(This article belongs to the Section Molecular Medicine)
  • Review
  • Open Access
64 Citations
9,538 Views
14 Pages

PD-L1–PD-1 Pathway in the Pathophysiology of Multiple Myeloma

  • Hideto Tamura,
  • Mariko Ishibashi,
  • Mika Sunakawa-Kii and
  • Koiti Inokuchi

10 April 2020

PD-L1 expressed on tumor cells contributes to disease progression with evasion from tumor immunity. Plasma cells from multiple myeloma (MM) patients expressed higher levels of PD-L1 compared with healthy volunteers and monoclonal gammopathy of undete...

(This article belongs to the Special Issue The Asymptomatic Version of Myeloma: MGUS and Smoldering Myeloma)
  • Article
  • Open Access
31 Citations
4,411 Views
10 Pages

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma

  • Kazuhiko Hashimoto,
  • Shunji Nishimura and
  • Masao Akagi

Recent data have suggested that PD-1 and PD-L1 are involved in osteosarcoma (OS) pathogenesis; however, their contributions are not well-established. Here, the PD-1/PD-L1 expression was evaluated in (OS) cases. Preoperative needle biopsy specimens we...

(This article belongs to the Special Issue Molecular Classification of Soft Tissue and Bone Tumors)
  • Review
  • Open Access
17 Citations
7,789 Views
23 Pages

Efficacy and Safety of PD-1/PD-L1 Checkpoint Inhibitors versus Anti-PD-1/PD-L1 Combined with Other Therapies for Tumors: A Systematic Review

  • Yiru Zhang,
  • Qigu Yao,
  • Yong Pan,
  • Xinru Fang and ,
  • Haoying Xu,
  • Tingxiao Zhao,
  • Guangqi Zhu,
  • Tianan Jiang,
  • Shibo Li and
  • Hongcui Cao
  • + 5 authors+ 0 author

22 January 2023

Objective: In recent years, the anti-programmed cell death protein-1 and its ligand (PD-1/PD-L1) or combination therapies have been recommended as an alternative emerging choice of treatment for oncology patients. However, the efficacy and adverse ev...

(This article belongs to the Topic Advances in Anti-Cancer Drugs)
  • Review
  • Open Access
44 Citations
10,042 Views
34 Pages

Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis

  • Fabian Krutzek,
  • Klaus Kopka and
  • Sven Stadlbauer

Immune checkpoint inhibitor (ICI) therapy has emerged as a major treatment option for a variety of cancers. Among the immune checkpoints addressed, the programmed death receptor 1 (PD-1) and its ligand PD-L1 are the key targets for an ICI. PD-L1 has...

(This article belongs to the Special Issue Forward Thinking towards Theranostic (Radio)ligands Targeting the Tumor Microenvironment (TME))
  • Article
  • Open Access
44 Citations
10,762 Views
23 Pages

PD-L1 Nanobody Competitively Inhibits the Formation of the PD-1/PD-L1 Complex: Comparative Molecular Dynamics Simulations

  • Xin Sun,
  • Xiao Yan,
  • Wei Zhuo,
  • Jinke Gu and ,
  • Ke Zuo,
  • Wei Liu,
  • Li Liang,
  • Ya Gan,
  • Gang He and
  • Jianping Hu
  • + 8 authors+ 3 authors

The anti-PD-L1 monoclonal antibody (mAb) targeting PD-1/PD-L1 immune checkpoint has achieved outstanding results in clinical application and has become one of the most popular anti-cancer drugs. The mechanism of molecular recognition and inhibition o...

(This article belongs to the Section Molecular Biophysics)
  • Article
  • Open Access
68 Citations
7,176 Views
13 Pages

The PD-L1/PD-1 Axis Blocks Neutrophil Cytotoxicity in Cancer

  • Olga Yajuk,
  • Maya Baron,
  • Sapir Toker,
  • Tamir Zelter and ,
  • Tanya Fainsod-Levi and
  • Zvi Granot
  • + 1 author+ 0 author

15 June 2021

The PD-L1/PD-1 axis mediates immune tolerance and promotes tumor growth and progression via the inhibition of anti-tumor immunity. Blocking the interaction between PD-L1 and PD-1 was clinically shown to be beneficial in maintaining the anti-tumor fun...

(This article belongs to the Special Issue The Role of Neutrophils in Cancer)
  • Article
  • Open Access
30 Citations
4,833 Views
10 Pages

Investigation of Various Pd Species in Pd/BEA for Cold Start Application

  • Beibei Zhang,
  • Meiqing Shen,
  • Jianqiang Wang,
  • Jiaming Wang and
  • Jun Wang

7 March 2019

A series of Pd/BEA catalysts with various Pd loadings were synthesized. Two active Pd2+ species, Z−-Pd2+-Z− and Z−-Pd(OH)+, on exchanged sites of zeolites, were identified by in situ FTIR using CO and NH3 respectively. Higher NOx st...

(This article belongs to the Special Issue Emissions Control Catalysis)
  • Review
  • Open Access
12 Citations
5,731 Views
15 Pages

Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas

  • Hiroo Katsuya,
  • Junji Suzumiya and
  • Shinya Kimura

14 November 2023

Immunotherapy with the programmed cell death protein 1 (PD-1)/PD-1 ligand (PD-L1) blockade has revolutionized the treatment of advanced solid cancers. However, these clinical benefits have been limited to cases of malignant lymphomas, showing promisi...

(This article belongs to the Special Issue Advances in Immunotherapy for Hematological Malignancies)
  • Review
  • Open Access
20 Citations
5,571 Views
22 Pages

The PD-1/PD-L1 Axis in the Biology of MASLD

  • Rosaria Maria Pipitone,
  • Giulia Lupo,
  • Rossella Zito,
  • Ayesha Javed and ,
  • Salvatore Petta,
  • Grazia Pennisi and
  • Stefania Grimaudo
  • + 2 authors+ 0 author

Metabolic Dysfunction-Associated Steatotic Liver (MASL), previously named nonalcoholic fatty liver (NAFL), is a multifactorial disease in which metabolic, genetic, and environmental risk factors play a predominant role. Obesity and type 2 diabetes ac...

(This article belongs to the Collection Immunopathology and Immunosenescence)
  • Article
  • Open Access
10 Citations
4,567 Views
21 Pages

Identification of CBPA as a New Inhibitor of PD-1/PD-L1 Interaction

  • Fengling Wang,
  • Wenling Ye,
  • Yongxing He,
  • Haiyang Zhong and ,
  • Yongchang Zhu,
  • Jianting Han,
  • Xiaoqing Gong,
  • Yanan Tian,
  • Yuwei Wang and
  • Xiaojun Yao
  • + 8 authors+ 3 authors

16 February 2023

Targeting of the PD-1/PD-L1 immunologic checkpoint is believed to have provided a real breakthrough in the field of cancer therapy in recent years. Due to the intrinsic limitations of antibodies, the discovery of small-molecule inhibitors blocking PD...

(This article belongs to the Special Issue Drug Design and Virtual Screening 2.0)
  • Review
  • Open Access
119 Citations
9,378 Views
18 Pages

PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects

  • Enrico Munari,
  • Francesca R. Mariotti,
  • Linda Quatrini,
  • Pietro Bertoglio and ,
  • Nicola Tumino,
  • Paola Vacca,
  • Albino Eccher,
  • Francesco Ciompi,
  • Matteo Brunelli and
  • Lorenzo Moretta
  • + 7 authors+ 2 authors

Immune evasion is a key strategy adopted by tumor cells to escape the immune system while promoting their survival and metastatic spreading. Indeed, several mechanisms have been developed by tumors to inhibit immune responses. PD-1 is a cell surface...

(This article belongs to the Special Issue Tumor Microenvironment: Interactions and Therapeutic Response)
  • Article
  • Open Access
45 Citations
8,119 Views
15 Pages

19 September 2019

The programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) is an immune checkpoint (ICP) overexpressed in various types of tumors; thus, it has been considered as an important target for cancer therapy. To determine important r...

(This article belongs to the Section Molecular Pharmacology)
  • Review
  • Open Access
29 Citations
8,297 Views
26 Pages

1 November 2022

Immunomodulation checkpoints usually adopted by healthy cells by tumors might cause an imbalance between host surveillance and tumor progression. Several tumors are incredibly resistant to standard treatment. The dynamic and long-lasting tumor regres...

(This article belongs to the Section Hematology and Immunology)
  • Article
  • Open Access
132 Citations
11,587 Views
16 Pages

Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors

  • Melanie Janning,
  • Franca Kobus,
  • Anna Babayan,
  • Harriet Wikman and ,
  • Janna-Lisa Velthaus,
  • Sonja Bergmann,
  • Stefanie Schatz,
  • Markus Falk,
  • Lars-Arne Berger and
  • Sonja Loges
  • + 17 authors+ 12 authors

17 June 2019

Circulating tumor cells (CTCs) hold great potential to answer key questions of how non-small cell lung cancer (NSCLC) evolves and develops resistance upon anti-PD-1/PD-L1 treatment. Currently, their clinical utility in NSCLC is compromised by a low d...

(This article belongs to the Special Issue Liquid Biopsy for Cancer)
  • Review
  • Open Access
14 Citations
7,727 Views
16 Pages

31 January 2025

Immune checkpoint blockade therapy, represented by anti-PD-1/PD-L1 monoclonal antibodies, has significantly changed the immunotherapy landscape. However, the treatment is still limited by unsatisfactory response rates, immune-related adverse effects,...

(This article belongs to the Section Molecular Immunology)
  • Article
  • Open Access
12 Citations
4,945 Views
13 Pages

Antitumor Effect of Korean Red Ginseng through Blockade of PD-1/PD-L1 Interaction in a Humanized PD-L1 Knock-In MC38 Cancer Mouse Model

  • Eun-Ji Lee,
  • Ju-Hye Yang,
  • Hye Jin Yang,
  • Chong-Kwan Cho and ,
  • Jang-Gi Choi and
  • Hwan-Suck Chung
  • + 1 author+ 0 author

18 January 2023

Blocking immune checkpoints, programmed death-1 (PD-1) and its ligand PD-L1, has proven a promising anticancer strategy for enhancing cytotoxic T cell activity. Although we previously demonstrated that ginsenoside Rg3, Rh2, and compound K block the i...

(This article belongs to the Special Issue Natural Products and Phytochemicals in Preventing and Treating Cancers)
  • Review
  • Open Access
102 Citations
9,648 Views
14 Pages

8 December 2019

It is obvious that tumor cells have developed a number of strategies to escape immune surveillance including an altered expression of various immune checkpoints, such as the programmed death-1 receptor (PD-1) and its ligands PD-L1 and PD-L2. The inte...

(This article belongs to the Special Issue Human Cancer Immunotherapy with Antibodies to the PD-1 and PD-L1 Pathway)
  • Article
  • Open Access
19 Citations
3,265 Views
20 Pages

The PD-1/PD-L1 Gateway: Peripheral Immune Regulation in the Pathogenesis of Endometriosis

  • Małgorzata Sobstyl,
  • Paulina Mertowska,
  • Sebastian Mertowski,
  • Monika Zaborek-Łyczba and ,
  • Dominik Dudziński,
  • Grzegorz Polak and
  • Ewelina Grywalska
  • + 2 authors+ 0 author

Endometriosis is a chronic inflammatory disease characterized by the presence of endometrial-like tissue outside the uterine cavity, causing pain and infertility. Despite the rather unclear etiopathogenesis, recent studies suggest the involvement of...

(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
  • Article
  • Open Access
18 Citations
4,510 Views
11 Pages

Virtual Screening and In Vitro Evaluation of PD-L1 Dimer Stabilizers for Uncoupling PD-1/PD-L1 Interaction from Natural Products

  • Jrhau Lung,
  • Ming-Szu Hung,
  • Yu-Ching Lin,
  • Chien-Hui Hung and ,
  • Chih-Cheng Chen,
  • Kuan-Der Lee and
  • Ying Huang Tsai
  • + 2 authors+ 0 author

13 November 2020

Genetic mutations accumulated overtime could generate many growth and survival advantages for cancer cells, but these mutations also mark cancer cells as targets to be eliminated by the immune system. To evade immune surveillance, cancer cells adopte...

(This article belongs to the Special Issue Recent Advances in Anticancer Drugs II)
  • Systematic Review
  • Open Access
18 Citations
7,222 Views
14 Pages

PD-1 and PD-L1 Expression in Endometrial Cancer: A Systematic Review of the Literature

  • Orazio De Tommasi,
  • Matteo Marchetti,
  • Marta Tripepi,
  • Sofia Bigardi and ,
  • Giosuè Giordano Incognito,
  • Valentina Tuninetti,
  • Emma Facchetti,
  • Giulia Tasca,
  • Marco Noventa and
  • Giulia Spagnol
  • + 7 authors+ 2 authors

10 January 2025

Background/Objectives: Cancer immunotherapy through the use of PD-1/PD-L1 inhibitors have shown significant promise in endometrial carcinoma (EC), particularly in tumors with microsatellite instability (MSI) or mismatch repair deficiency (dMMR), pres...

(This article belongs to the Section Obstetrics & Gynecology)
  • Article
  • Open Access
28 Citations
5,481 Views
14 Pages

Catalytic Oxidation of Chlorobenzene over Pd-TiO2 /Pd-Ce/TiO2 Catalysts

  • Wenjun Liang,
  • Xiaoyan Du,
  • Yuxue Zhu,
  • Sida Ren and
  • Jian Li

20 March 2020

A series of Pd-TiO2/Pd-Ce/TiO2 catalysts were prepared by an equal volume impregnation method. The effects of different Pd loadings on the catalytic activity of chlorobenzene (CB) were investigated, and the results showed that the activity of the 0.2...

(This article belongs to the Special Issue Metal/Metal Oxide-Support Interactions in Heterogeneous Catalysis)
  • Review
  • Open Access
18 Citations
10,834 Views
28 Pages

A Comprehensive Computational Insight into the PD-L1 Binding to PD-1 and Small Molecules

  • Marialuigia Fantacuzzi,
  • Roberto Paciotti and
  • Mariangela Agamennone

28 February 2024

Immunotherapy has marked a revolution in cancer therapy. The most extensively studied target in this field is represented by the protein–protein interaction between PD-1 and its ligand, PD-L1. The promising results obtained with the clinical us...

(This article belongs to the Special Issue Computational Methods in the Design of Anticancer Drugs)
  • Review
  • Open Access
35 Citations
7,130 Views
22 Pages

The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers

  • Omid Kooshkaki,
  • Afshin Derakhshani,
  • Hossein Safarpour,
  • Souzan Najafi and ,
  • Parviz Vahedi,
  • Oronzo Brunetti,
  • Mitra Torabi,
  • Parisa Lotfinejad,
  • Angelo Virgilio Paradiso and
  • Behzad Baradaran
  • + 7 authors+ 2 authors

Gynecologic cancers account for approximately 11% of the newly diagnosed cancers in women in the United States and for 18% globally. The presence of tumor-infiltrating lymphocytes (TILs) influences the clinical outcome of cancer patients and immune c...

(This article belongs to the Special Issue The Immune Landscape in Solid Tumors)
  • Article
  • Open Access
15 Citations
5,023 Views
16 Pages

Quantification of Pharmacokinetic Profiles of PD-1/PD-L1 Antibodies by Validated ELISAs

  • Sara Zalba,
  • Ana M. Contreras-Sandoval,
  • Eva Martisova,
  • Reno Debets and ,
  • Christian Smerdou and
  • María Jesús Garrido
  • + 1 author+ 0 author

Immunotherapy has changed the paradigm of cancer treatments. In this way, several combinatorial strategies based on monoclonal antibodies (mAb) such as anti (a)-PD-1 or anti (a)-PD-L1 are often reported to yield promising clinical benefits. However,...

  • Review
  • Open Access
18 Citations
6,837 Views
15 Pages

The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia

  • Laura Jimbu,
  • Oana Mesaros,
  • Alexandra Neaga,
  • Ana Maria Nanut and ,
  • Ciprian Tomuleasa,
  • Delia Dima,
  • Corina Bocsan and
  • Mihnea Zdrenghea
  • + 3 authors+ 0 author

29 October 2021

Tumor cells promote the suppression of host anti-tumor type 1 T cell responses by various mechanisms, including the upregulation of surface inhibitory molecules such as programmed death ligand (PD-L)-1, and the production of immunosuppressive cytokin...

  • Review
  • Open Access
20 Citations
10,815 Views
17 Pages

PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas

  • Wei Xie,
  • L. Jeffrey Medeiros,
  • Shaoying Li,
  • Guilin Tang and ,
  • Guang Fan and
  • Jie Xu
  • + 1 author+ 0 author

The programmed death-ligands, PD-L1 and PD-L2, reside on tumor cells and can bind with programmed death-1 protein (PD-1) on T-cells, resulting in tumor immune escape. PD-1 ligands are highly expressed in some CD30+ large cell lymphomas, including cla...

(This article belongs to the Special Issue State-of-the-Art Immunology and Immunotherapy in USA)
  • Communication
  • Open Access
1 Citations
3,076 Views
7 Pages

Divergent Cellular Expression Patterns of PD-L1 and PD-L2 Proteins in Breast Cancer

  • Julie M. Jorns,
  • Yunguang Sun,
  • Sailaja Kamaraju,
  • Yee Chung Cheng and ,
  • Amanda Kong,
  • Tina Yen,
  • Caitlin R. Patten,
  • Chandler S. Cortina,
  • Christopher R. Chitambar and
  • Lubna N. Chaudhary
  • + 6 authors+ 1 author

29 April 2024

PD-L1 immunohistochemistry (IHC) has become an established method for predicting cancer response to targeted anti-PD1 immunotherapies, including breast cancer (BC). The alternative PD-1 ligand, PD-L2, remains understudied but may be a complementary p...

(This article belongs to the Special Issue Breast Cancer: Molecular Mechanisms, Diagnosis Techniques and Therapeutic Targets)
  • Review
  • Open Access
43 Citations
10,304 Views
22 Pages

Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on Biomarkers

  • Areti Strati,
  • Christos Adamopoulos,
  • Ioannis Kotsantis,
  • Amanda Psyrri and ,
  • Evi Lianidou and
  • Athanasios G. Papavassiliou
  • + 1 author+ 0 author

31 January 2025

The PD1/PD-L1 axis plays an important immunosuppressive role during the T-cell-mediated immune response, which is essential for the physiological homeostasis of the immune system. The biology of the immunological microenvironment is extremely complex...

(This article belongs to the Special Issue Immunotherapy: A New Perspective in Cancer Treatment)
  • Article
  • Open Access
250 Views
12 Pages

PD-1 and PD-L1 Expression in Inflammatory Bowel Disease: A Paired Immunohistochemical Study

  • Harald Bagger-Jörgensen,
  • Christian Thomsen and
  • Klas Sjöberg

Background/Objectives: The significance of the PD-1/PD-L1 immune checkpoint pathway in inflammatory bowel disease (IBD) is highlighted by side effects from checkpoint inhibitor therapies including autoimmune enterocolitis reminiscent of IBD. Methods:...

(This article belongs to the Section Gene and Cell Therapy)
  • Review
  • Open Access
22 Citations
8,775 Views
17 Pages

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy

  • Ana Bocanegra,
  • Ester Blanco,
  • Gonzalo Fernandez-Hinojal,
  • Hugo Arasanz and ,
  • Luisa Chocarro,
  • Miren Zuazo,
  • Pilar Morente,
  • Ruth Vera,
  • David Escors and
  • Grazyna Kochan
  • + 5 authors+ 0 author

18 August 2020

The use of monoclonal antibodies targeting PD-1/PD-L1 axis completely changed anticancer treatment strategies. However, despite the significant improvement in overall survival and progression-free survival of patients undergoing these immunotherapy t...

(This article belongs to the Special Issue PD-L1, a Master Regulator of Immunity 2.0)
  • Review
  • Open Access
46 Citations
6,429 Views
15 Pages

Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer

  • Florus C. de Jong,
  • Vera C. Rutten,
  • Tahlita C. M. Zuiverloon and
  • Dan Theodorescu

In high-risk non-muscle invasive bladder cancer (HR-NMIBC), patient outcome is negatively affected by lack of response to Bacillus-Calmette Guérin (BCG) treatment. Lack of response to cisplatin-based neoadjuvant chemotherapy and cisplatin ineligibili...

(This article belongs to the Special Issue Cancer Immunotherapy Using Checkpoint Inhibitors: Future Directions 2.0)
  • Review
  • Open Access
73 Citations
17,371 Views
14 Pages

The therapy of different advanced-stage malignancies with monoclonal antibodies blocking programmed cell death protein 1 (PD-1)/PD-1 ligand 1 (PD-L1) signaling has had an impressive long-lasting effect in a portion of patients, but in most cases, thi...

(This article belongs to the Special Issue Targeting Immune Checkpoints and Immunotherapy)
  • Review
  • Open Access
28 Citations
6,662 Views
25 Pages

7 September 2021

Immune checkpoints refer to a range of immunoregulatory molecules that modulate the immune response. For example, proteins expressed at the surface of T-cells (including PD-1 and CTLA-4) and their ligands (PD-L1 and B7-1/B7-2, respectively), expresse...

(This article belongs to the Special Issue Combination Therapy Strategies for Cancer PD-1/PD-L1 Pathway Blockade Awareness)
  • Article
  • Open Access
11 Citations
5,222 Views
10 Pages

PD-L1/PD-1 and CTLA-4 Expression in Equine Penile Squamous Cell Carcinomas

  • Ilaria Porcellato,
  • Samanta Mecocci,
  • Chiara Brachelente,
  • Katia Cappelli and ,
  • Federico Armando,
  • Alessia Tognoloni,
  • Elisabetta Chiaradia,
  • Valentina Stefanetti,
  • Luca Mechelli and
  • Elisabetta Razzuoli
  • + 9 authors+ 4 authors

16 July 2021

In horses, penile squamous cell carcinomas (epSCCs) are among the most common cutaneous neoplastic lesions. These tumors usually arise in benign lesions such as viral plaques and papillomas frequently induced by Equus caballus papillomavirus type 2 (...

(This article belongs to the Section Equids)
  • Review
  • Open Access
21 Citations
11,824 Views
20 Pages

4 October 2022

The programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) pathway mainly attracted attention in immuno-oncology, leading to the development of immune checkpoint therapy. It has, however, much broader importance for tissue physiology...

  • Article
  • Open Access
30 Citations
8,402 Views
23 Pages

Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy

  • Hongbo Zhang,
  • Yu Xia,
  • Chunqiu Yu,
  • Huijie Du and ,
  • Jinchang Liu,
  • Hui Li,
  • Shihui Huang,
  • Qihua Zhu,
  • Yungen Xu and
  • Yi Zou
  • + 5 authors+ 0 author

Blockade of the programmed cell death 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction is currently the focus in the field of cancer immunotherapy, and so far, several monoclonal antibodies (mAbs) have achieved encouraging outcomes in canc...

(This article belongs to the Special Issue Medicinal Chemistry in China)
  • Review
  • Open Access
40 Citations
11,019 Views
16 Pages

15 March 2023

The advent of immunotherapy, especially immune checkpoint inhibitors (ICIs), has revolutionized antitumor therapy. Programmed cell death receptor 1 (PD-1) and programmed cell death ligand 1 (PD-L1) are among the most promising targets for encouraging...

(This article belongs to the Section Personalized Therapy and Drug Delivery)
  • Article
  • Open Access
36 Citations
6,644 Views
11 Pages

Expression of PD-1 and PD-L1 in Extramammary Paget Disease: Implications for Immune-Targeted Therapy

  • Shakuntala H. Mauzo,
  • Michael T. Tetzlaff,
  • Denái R. Milton,
  • Alan E. Siroy and ,
  • Priyadharsini Nagarajan,
  • Carlos A. Torres-Cabala,
  • Doina Ivan,
  • Jonathan L. Curry,
  • Courtney W. Hudgens and
  • Phyu P. Aung
  • + 9 authors+ 4 authors

29 May 2019

Extramammary Paget disease (EMPD) is a locally aggressive cutaneous malignancy that usually arises in anogenital or axillary skin. Immune checkpoint inhibitors targeting programmed cell death receptor (PD-1) and/or its ligand (PD-L1) are approved for...

(This article belongs to the Special Issue Signaling Pathways and Immune Checkpoint Regulation in Cancer)
  • Review
  • Open Access
67 Citations
10,357 Views
30 Pages

Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges

  • Fang Yang,
  • Jacqueline F. Wang,
  • Yucai Wang,
  • Baorui Liu and
  • Julian R. Molina

27 December 2021

Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) have dramatically changed the landscape of cancer therapy. Both remarkable and durable responses have been observed in patients wit...

(This article belongs to the Special Issue Cancer Immunotherapy and Immune-Related Adverse Events)
  • Review
  • Open Access
78 Citations
8,440 Views
17 Pages

Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma

  • Solène-Florence Kammerer-Jacquet,
  • Antoine Deleuze,
  • Judikaël Saout,
  • Romain Mathieu and ,
  • Brigitte Laguerre,
  • Gregory Verhoest,
  • Frédéric Dugay,
  • Marc-Antoine Belaud-Rotureau,
  • Karim Bensalah and
  • Nathalie Rioux-Leclercq
  • + 5 authors+ 0 author

Renal cell carcinoma encompass distinct diseases with different pathologic features and distinct molecular pathways. Immune checkpoint inhibitors targeting the programmed death receptor ligand 1 (PD-L1)/programmed death receptor 1 (PD-1) pathway alon...

(This article belongs to the Special Issue PD-L1, A Master Regulator of Immunity)

of 391